{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T08:15:00Z","timestamp":1788077700859,"version":"build-2784847793"},"reference-count":33,"publisher":"Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:p>Background: Doxofylline (DFL) is a medication widely employed in the management of asthma and chronic obstructive pulmonary disease. Evodiamine (EVO), a bioactive alkaloid from traditional Chinese medicine (TCM), is commonly utilized for treating hypertension, gastropathy, and eczema. Cytochrome P450 enzymes primarily mediate the metabolism of both pharmaceuticals and TCMs in-vivo, which potentially lead to drug-drug interactions. Objectives: This study aimed to investigate the effects of oral EVO on the pharmacokinetics (PK) of DFL and its metabolite, theophylline (TPL), in rats. Methods: Twelve rats were randomly assigned to control and experimental groups. The experimental group received 50 mg\/kg EVO orally once daily for one week, while the control group received 0.5% sodium carboxymethyl cellulose. On day 7, DFL (80 mg\/kg) was administered 2 h post-treatment. Venous blood specimens were collected from the retro-orbital venous plexus at 0.1667, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 48 h post-dose. Plasma concentrations of DFL and TPL were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS\/MS). Results: Compared with the control group, the experimental group showed significant alterations in several PK parameters for both DFL and TPL. The administration of EVO markedly increased MRT(0-?), MRT(0-t), VRT(0-?), VRT(0-t), t1\/2z, and Vz\/F for DFL while also enhancing CLz\/F and Vz\/F for TPL. Conversely, EVO notably decreased AUC(0-?), AUC(0-t), and MRT(0-t) values associated with TPL. Conclusion: Concomitant administration of EVO alongside DFL resulted in substantial modifications to key PK parameters concerning both DFL and its metabolite TPL in rats. Specifically, EVO prolonged the retention time and increased the volume of distribution of DFL, while simultaneously reducing the bioavailability and accelerating the clearance of TPL (P&lt;0.05). Therefore, it is imperative to closely monitor the impact of TCM EVO on the PKs of DFL and TPL in experimental animals, necessitating further research and clinical observation.<\/jats:p>","DOI":"10.36721\/pjps.2026.39.9.258.1","type":"journal-article","created":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T07:48:28Z","timestamp":1782632908000},"source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetic interaction between evodiamine and doxofylline in rats"],"prefix":"10.36721","author":[{"given":"Yuxian","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22735","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Al-Shami A, Mohamed MA, Ma H, Nejad SK, Soleimani A, Amirghasemi F, Banks M, Garcia D, Tasso A, Yaseen AA and Mousavi MPS (2025). quantification theophylline\u2002A point-of-care device for in human milk using laser-induced graphene electrodes. ACS. Appl. Nano. Mater., 8(22): 11447-11457.","DOI":"10.1021\/acsanm.5c01407"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Campbell JL Jr, Travis KZ, Clewell HJ 3rd, Stevens AJ, Hinderliter PM andersen ME, Botham PA, Cook AR, Minnema DJ and Wolf DC (2021). Integration of paraquat pharmacokinetic data across species using PBPK modelling. Toxicol. Appl. Pharmacol., 417: 115462.","DOI":"10.1016\/j.taap.2021.115462"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Cao Q, Liu J, Dong P and Han H (2023). Different ratios of schisandra combination for treating Alzheimer's disease\u2002chinensis and evodia rutaecarpa. Exp. Biol. Med (Maywood), 248(20): 1877-1886.","DOI":"10.1177\/15353702231199075"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Castillo-Ribelles L, Arranz-Amo JA, Hernandez-Vara J, Ferrer-Costa R, Martinez-Vicente M and Carnicer-Caceres C (2025). Systematic assessment of matrix effect, recovery and process efficiency using three complementary approaches: Implications for LC-MS\/MS bioanalysis applied to glucosylceramides in human cerebrospinal fluid. ACS Omega., 10(44): 52449-52458.","DOI":"10.1021\/acsomega.5c05399"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Fang LN, Mao MQ, Zhao XH, Yang L, Jia H, Xia SY (2019). Development and validation of a UPLC-MS\/MS method for quantification of doxofylline and its metabolites in human plasma. J. Pharm. Biomed. Anal., 174: 220-225.","DOI":"10.1016\/j.jpba.2019.05.039"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Fierro V, Piscitelli AL, Battaglia E and Fiocchi A (2022). Doxofylline for pediatric asthma steps 1-4. pediatric asthma: New role for an dld drug. Front. Pediatr., 10:772704.","DOI":"10.3389\/fped.2022.772704"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Haiss P, Liu R, Xian F, Varela DG, Schmidt M, Dirsch VM and Blazevic T (2025). Evodiamine induces centrosome amplification with subsequent G2\/M cell cycle arrest in primary vascular smooth muscle cells. Biochem. Pharmacol., 242(Pt 2): 117320.","DOI":"10.1016\/j.bcp.2025.117320"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Harstad E andaya R, Couch J, Ding X, Liang X, Liederer BM, Messick K, Nguyen T, Schweiger M, Tarrant J, Zhong S and Dean B (2016). Balancing blood sample volume with 3Rs: Implementation and best practices for small molecule toxicokinetic assessments in rats. ILAR J., 57(2):157-165.","DOI":"10.1093\/ilar\/ilw023"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Li RF, Fu JM, Lv XZ, Zhang DT, Pan YY, Rao DP and Yu KY (2016). Effects of evodiamine on the pharmacokinetics of dapoxetine and its metabolite desmethyl dapoxetine in rats. Pharmacology, 97(1-2): 43-7.","DOI":"10.1159\/000441568"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Li XP, Zhang CL, Gao P, Gao J and Liu D (2013). Effects of andrographolide on the pharmacokinetics of aminophylline and doxofylline in rats. Drug Res (Stuttg), 63(5): 258-62.","DOI":"10.1055\/s-0033-1341432"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Liang R, Ge W, Li B, Cui W, Ma X, Pan Y and Li G (2022). Evodiamine decreased the systemic exposure of pravastatin in non-alcoholic steatohepatitis rats due to the up-regulation of hepatic OATPs. Pharm. Biol., 60(1): 359-373.","DOI":"10.1080\/13880209.2022.2036767"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Liu CY, Wu JH, Chen ZY, Zhang Y, Huang CL, Lin AM, Xu XT and Gao XH (2021). Effect of doxofylline on reducing the inflammatory response in mechanically ventilated rats with chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis., 16: 2375-2383.","DOI":"10.2147\/COPD.S315639"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Ma YJ, Jiang DQ, Meng JX, Li MX, Zhao HH, Wang Y and Wang LQ (2016). Theophylline: A review of population pharmacokinetic analyses. J. Clin. Pharm. Ther., 41(6): 594-601.","DOI":"10.1111\/jcpt.12435"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Mariappan TT, Kurawattimath V, Gautam SS, Kulkarni CP, Kallem R, Taskar KS, Marathe PH and Mandlekar S (2014). Estimation of the unbound brain concentration of P-glycoprotein substrates or nonsubstrates by a serial cerebrospinal fluid sampling technique in rats. Mol. Pharm., 11(2): 477-85.","DOI":"10.1021\/mp400436d"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Matera MG, Page C and Cazzola M (2017). Doxofylline is not just another theophylline. Int. J. Chron. Obstruct. Pulmon. Dis., 12: 3487-3493.","DOI":"10.2147\/COPD.S150887"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Moreira LN, Feltrin C, Gon\u00e7alves JE, de Castro WV, Simoes CMO, de Padua RM, Cortes SF and Braga FC (2020). Determination of l-(+)-bornesitol, the hypotensive constituent of Hancornia speciosa, in rat plasma by LC-MS\/MS and its application on a pharmacokinetic study. Biomed. Pharmacother., 132: 110900.","DOI":"10.1016\/j.biopha.2020.110900"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Panda M, Tripathi SK, Zengin G and Biswal BK (2023). Evodiamine as an anticancer agent: A comprehensive review on its therapeutic application, pharmacokinetic, toxicity and metabolism in various cancers. Cell Biol Toxicol, 39(1): 1-31.","DOI":"10.1007\/s10565-022-09772-8"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Papadopoulos NG, Miligkos M and Xepapadaki P (2022). A current perspective of allergic asthma: From mechanisms to management. Handb. Exp. Pharmacol., 268: 69-93.","DOI":"10.1007\/164_2021_483"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Peng T, Rao J, Zhang T, Wang Y, Li N, Gao Q, Feng X, Song Z, Wang K and Qiu F (2023). Elucidation of the relationship injury and CYP3A4-mediated metabolic\u2002liver\u2002evodiamine-induced\u2002between activation by UPLC-MS\/MS analysis. Anal. Bioanal. Chem., 415(23): 5619-5635.","DOI":"10.1007\/s00216-023-04831-3"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Rao RN, Prasad KG, Naidu ChG, Saida S and Agwane SB (2013). Development of a validated on rat dried blood spots\u2002doxofylline\u2002LC-MS\/MS method for determination of urine: Application to pharmacokinetics.  J. Pharm. Biomed. Anal., 78-79: 211-6.","DOI":"10.1016\/j.jpba.2013.02.017"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Sun Q, Xie L, Song J and Li X (2020). Evodiamine: A review of its pharmacology, toxicity, pharmacokinetics and preparation researches. J. Ethnopharmacol., 262: 113164.","DOI":"10.1016\/j.jep.2020.113164"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Takeda F, Oda M, Terasaki M, Kubota A, Asada K, Ichimura Y, Kojima H and Saitoh H (2021). Downregulated expression of organic anion transporting polypeptide (Oatp) 2b1 in the small intestine of rats with acute kidney injury. Drug Metab. Pharmacokinet., 40: 100411.","DOI":"10.1016\/j.dmpk.2021.100411"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Wang Q, Cui Y, Wu X and Wang J (2021). Evodiamine protects against airway remodelling and inflammation in asthmatic rats by modulating the HMGB1\/NF-\u03baB\/TLR-4 signalling pathway. Pharm. Biol., 59(1): 192-199.","DOI":"10.1080\/13880209.2020.1871374"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Wang T, Qi D, Hu X, Li N, Zhang X, Liu H, Zhong C and Zhang J (2021). A novel evodiamine amino derivative as a PI3K\/AKT signaling pathway modulator that induces apoptosis in small cell lung cancer cells. Eur. J. Pharmacol., 906:174215.","DOI":"10.1016\/j.ejphar.2021.174215"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Wen B, Roongta V, Liu L and Moore DJ (2014). Metabolic activation of the indoloquinazoline alkaloids evodiamine and rutaecarpine by human liver microsomes: Dehydrogenation and inactivation of cytochrome P450 3A4. Drug Metab. Dispos., 42(6): 1044-54.","DOI":"10.1124\/dmd.114.057414"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Wu TD, Brigham EP and McCormack MC (2019). Asthma in the primary care setting. Med. Clin. North. Am., 103(3): 435-452.","DOI":"10.1016\/j.mcna.2018.12.004"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Yang KH, Lee JH and Lee MG (2008). Effects of CYP inducers and inhibitors on the pharmacokinetics of intravenous theophylline in rats: Involvement of CYP1A1\/2 in the formation of 1,3-DMU. J. Pharm. Pharmacol., 60(1): 45-53.","DOI":"10.1211\/jpp.60.1.0006"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Yang Y, Wu P, Guo J, Pan Z, Lin S, Zeng W, Wang C, Dong Z and Wang S (2024). Circadian disposition and\u2002theophylline\u2002time-dependent effects of experimental colitis on toxicity. Br. J. Pharmacol., 181(19): 3743-3759.","DOI":"10.1111\/bph.16440"},{"key":"ref28","unstructured":"Yuxian LIN, Peipei PAN, Jianhua XIONG, Lianguo CHEN, Qiong WANG, Shujun WANG, Lirong SUN and Guoxin HU (2015). Alcohol affects the pharmacokinetics of doxofylline and its metabolite theophylline in rats. Lat. Am. J. Pharm., 34(6): 1065-1069."},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Zha Y, Yang Y, Zhou Y, Ye B, Li H and Liang J (2023). Dietary Evodiamine inhibits atherosclerosis-associated changes in vascular smooth muscle cells. Int. J. Mol. Sci., 24(7): 6653.","DOI":"10.3390\/ijms24076653"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Zhang YT, Zhang DF, Ge NY, Zhu GH, Hao C, Zhang Y and Chen RJ (2016). Effect of evodiamine on CYP enzymes in rats by a cocktail method. Pharmacology, 97(5-6): 218-23.","DOI":"10.1159\/000443178"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Zhao J, Zhang Q, Zou G, Gao G and Yue Q (2020). Corrigendum to \"Arenobufagin, isolated from toad venom, inhibited epithelial-to-mesenchymal transition and suppressed migration and invasion of lung cancer cells via targeting IKK\u03b2\/NF\u03baB signal cascade\". J. Ethnopharmacol., 250(25): 112492","DOI":"10.1016\/j.jep.2019.112492"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Zhao X, Ma H, Pan Q, Wang H, Qian X, Song P, Zou L, Mao M, Xia S, Ge G and Yang L (2020). Theophylline acetaldehyde as the initial product in doxophylline metabolism in human liver. Drug Metab. Dispos., 48(5): 345-352.","DOI":"10.1124\/dmd.119.089565"}],"container-title":["Pakistan Journal of Pharmaceutical Sciences"],"original-title":[],"deposited":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T07:57:02Z","timestamp":1788076622000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.pjps.pk\/single-article?id=7863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":33,"URL":"https:\/\/doi.org\/10.36721\/pjps.2026.39.9.258.1","relation":{},"ISSN":["1011-601X","3105-9686"],"issn-type":[{"value":"1011-601X","type":"print"},{"value":"3105-9686","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]}}}